HK stocks surged, Shares of Mega Vision Group rose more than 5%, and the antiglaucoma drug Jingbeiqing was approved by the National Medical Products Administration for listing.

Gelonghui Finance · Sep 20 09:22

On September 20th, Chia Tai Ophthalmology-B (6622.HK) opened at a high of 5.19% and reported HK$1.42. In terms of news, the company announced that its research and development of the anti-glaucoma drug Beminitan prostaglandin eye drops (Cinzin) has been approved by the National Medical Products Administration for listing. The company stated that the Beminitan prostaglandin eye drops is the first single-dose Beminitan prostaglandin eye drops in China without preservatives, and is used to reduce intraocular pressure in patients with angle-closure glaucoma and ocular hypertension.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

港股异动丨兆科眼科高开超5%，抗青光眼药物晶贝清获国家药监局批准上市

HK stocks surged, Shares of Mega Vision Group rose more than 5%, and the antiglaucoma drug Jingbeiqing was approved by the National Medical Products Administration for listing.

Risk Disclaimer

Statement